Allianz Asset Management’s GenMark Diagnostics, Inc GNMK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-94,805
Closed -$2.27M 2533
2021
Q1
$2.27M Sell
94,805
-194,661
-67% -$3.62M ﹤0.01% 1358
2020
Q4
$4.23M Buy
289,466
+33,648
+13% +$446K ﹤0.01% 1096
2020
Q3
$3.63M Buy
255,818
+137,341
+116% +$2.1M ﹤0.01% 1080
2020
Q2
$1.74M Buy
+118,477
New +$1.2M ﹤0.01% 1661
2018
Q1
Sell
-273,636
Closed -$1.14M 2786
2017
Q4
$1.14M Sell
273,636
-3,299
-1% -$19.9K ﹤0.01% 2201
2017
Q3
$2.67M Buy
276,935
+6,469
+2% +$67.2K ﹤0.01% 1896
2017
Q2
$3.2M Buy
270,466
+18,842
+7% +$241K ﹤0.01% 1804
2017
Q1
$3.23M Buy
251,624
+7,074
+3% +$85.1K ﹤0.01% 1817
2016
Q4
$2.99M Sell
244,550
-38,506
-14% -$457K ﹤0.01% 1823
2016
Q3
$3.34M Buy
+283,056
New +$2.73M ﹤0.01% 1786
2013
Q3
Sell
-224,799
Closed -$2.33M 1857
2013
Q2
$2.33M Buy
+224,799
New +$3.1M ﹤0.01% 1160

Allianz Asset Management's GNMK Position: Q2 2021 in Review

Allianz Asset Management sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2021, closing a stake of 94,805 shares — an estimated $2.27M sold.

Allianz Asset Management first reported a position in GNMK in Q2 2013 and held it in 11 quarters. The position peaked at $4.23M in Q4 2020. 0 funds tracked by Wall St. Rank hold GNMK as of Q2 2021.

  • Allianz Asset Management reported no remaining GenMark Diagnostics, Inc position as of Q2 2021 after selling out during the quarter.
  • Allianz Asset Management sold 94,805 GenMark Diagnostics, Inc shares in Q2 2021, an estimated $2.27M.
  • Allianz Asset Management first reported a position in GenMark Diagnostics, Inc in Q2 2013 and held it in 11 quarters.
  • Allianz Asset Management's GenMark Diagnostics, Inc position peaked at $4.23M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2021.

Based on Allianz Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.